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ABSTRACT
Objective  To determine human leucocyte antigen-
class II (HLA-class II) (DRB1, DQB1, DQA1 and DPB1) 
alleles, haplotypes and shared epitopes associated 
with scleroderma (systemic sclerosis (SSc)) and its 
subphenotypes in a large multi-ethnic US cohort by a 
case–control association study.
Patients and methods  1300 SSc cases (961 white, 
178 black and 161 Hispanic subjects) characterised 
for clinical skin forms (limited vs diffuse), SSc-
speciﬁ  c autoantibodies (anticentromere (ACA), 
anti-topoisomerase I (ATA), anti-RNA polymerase III 
(ARA), anti-U3 ribonucleoprotein (ﬁ  brillarin)) and others 
were studied using molecular genotyping. Statistical 
analyses in SSc itself by ethnicity, gender, skin type 
and autoantibodies were performed using exact logistic 
regression modelling for dominant, additive and recessive 
effects from HLA.
Results  The strongest positive class II associations 
with SSc in white and Hispanic subjects were the 
DRB1*1104, DQA1*0501, DQB1*0301 haplotype and 
DQB1 alleles encoding a non-leucine residue at position 
26 (DQB1 26 epi), while the DRB1*0701, DQA1*0201, 
DQB1*0202 haplotype and DRB1*1501 haplotype were 
negatively correlated and possibly protective in dominant 
and recessive models, respectively. These associations 
did not discriminate between limited and diffuse SSc. 
SSc in black subjects was associated with DRB1*0804, 
DQA1*0501, DQB1*0301 alleles. DPB1*1301 showed 
the highest odds ratio for ATA (OR = 14). Moreover, it 
showed no linkage disequilibrium or gene interaction with 
DR/DQ. ACA was best explained by DQB1*0501 and 
DQB1*26 epi alleles and ARA by DRB1*0404, DRB1*11 
and DQB1*03 alleles in white and Hispanic subjects but 
DRB1*08 in black subjects.
Conclusion  These data indicate unique and multiple 
HLA-class II effects in SSc, especially on autoantibody 
markers of different subphenotypes.
INTRODUCTION
Scleroderma (systemic sclerosis, SSc) is a chronic 
complex autoimmune disease characterised by 
(a) organ ﬁ  brosis involving the skin, lungs, gastro-
intestinal tract and/or heart; (b) a proliferative vas-
culopathy primarily affecting small blood vessels 
and capillaries; (c) immune activation with pro-
duction of disease-speciﬁ  c autoantibodies.1–4 The 
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disease is further classiﬁ  ed into limited and diffuse 
forms based on extent and distribution of cutane-
ous thickening.
The most common SSc-speciﬁ  c   autoantibodies 
are directed against centromeric proteins anticen-
tromere (ACA) (CENP B and A), anti-topoisomerase 
I (ATA) (also termed Scl-70) and anti-RNA poly-
merase III (ARA); however, a variety of less com-
mon speciﬁ   cities, typically antinucleolar, can be 
found, which include anti-U3 ribonucleoprotein 
(ﬁ   brillarin) AFA), anti-Th/To, anti-Pm-Scl, anti-
RNA polymerase I and anti-U1-ribonucleoprotein 
(RNP).5 Importantly, each patient with SSc typi-
cally produces only one of these autoantibodies 
and each one currently serves as a biomarker for 
different patterns of skin and visceral involve-
ment, as well as prognosis. In addition, certain SSc-
speciﬁ   c antibodies occur in different frequencies 
among different ethnic groups.
Scleroderma is thought to be a complex genetic 
disease, inﬂ  uenced by multiple genes, with a sub-
stantial environmental or non-germline component 
based on twin studies.6 African-American and 
Hispanic patients with scleroderma tend to have 
more severe disease than their Caucasian coun-
terparts and disease in African-American subjects 
begins at an earlier age.7 The Choctaw Indians 
of southeastern Oklahoma have a nearly 10-fold 
prevalence of the disease compared with other eth-
nicities.8 It appears likely that there are different 
combinations of genes, the interacting effects of 
which inﬂ  uence disease susceptibility and severity. 
Recently, we have found that the same polymor-
phism in the PTPN22 gene associated with rheu-
matoid arthritis, systemic lupus erythematosus 
and other autoimmune diseases is also associated 
with SSc, especially in those patients having ATA 
or ACA antibodies.9–11 Additional ‘autoimmunity’ 
genes now reported to be associated with SSc 
include allograft inﬂ  ammatory factor, IL1A, IRF5, 
STAT4 and FAS.12–16
Major histocompatibility complex (MHC) or 
human leucocyte antigen-class II (HLA-class II) 
allelic associations with SSc have been reported 
in European and North American Caucasian 
subjects (DRB1*0301, DRB1*11, DRB1*07) and 
Japanese and Koreans (DRB1*1502) over the past 
two decades but have been relatively weak.5 17–22 
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Much stronger correlations, however, have been demonstrated 
between certain HLA-class II alleles and each of the SSc-speciﬁ  c 
autoantibodies.21 23–27 Different HLA-DRB1, DQB1, DQA1 and/
or DPB1 alleles, or combinations thereof, are associated with 
expression of ACA (DQB1*0501 and other DQB1 alleles encod-
ing non-leucine residues at position 26 in the peptide bind-
ing groove),21 25 27 ATA (DRB1*11, especially the DRB1*1104, 
DQB1*0301 haplotype) in Caucasian subjects and DRB1*1502, 
DQB1*0601 in Japanese and Korean subjects,21–23 AFA anti-
body (the DRB1*1302, DQB1*0604 haplotype),24 and anti-PM-
Scl (DRB1*0301).26 No consistent HLA correlations heretofore 
have been made with ARA.28 29 38–40 Only a few studies have 
examined HLA-DPB1 alleles in SSc; however, one such allele 
(DPB1*1301) has been associated with ATA.30–32 It has been 
unclear whether this allele is an independent disease correlate 
or the result of linkage disequilibrium (LD) with HLA-DRB1 and 
DQB1 haplotypes. Although genetic inﬂ  uences are thought to 
have an important role in susceptibility to SSc, genetic studies of 
scleroderma have included relatively small numbers of patients, 
especially black and Hispanic subjects. HLA associations with 
speciﬁ  c autoantibodies may be clinically relevant because each 
of the autoantibody subsets of scleroderma is associated with 
certain disease features and different prognostic implications.
Thus, the overall aims of this study were to determine speciﬁ  c 
HLA-class II alleles, haplotypes and epitopes inﬂ  uencing suscep-
tibility to, and/or expression of, SSc itself, its limited or diffuse 
forms, or its various autoantibody subsets across ethnic lines in 
the largest cohort yet of American patients.
METHODS
Selection of SSc cases and normal controls
A case–control association study was performed (total SSc cases 
1300; total controls 1000) along with subanalyses by ethnic-
ity, gender, clinical subsets and speciﬁ  c autoantibody proﬁ  les. 
Patients were included from the NIH/NIAMS Scleroderma 
Family Registry and DNA Repository,33 the Genetics versus 
Environment in Scleroderma Outcomes Study (GENISOS) cohort 
followed up in the NIH/NIAMS Center of Research Translation 
in Scleroderma,6 and the UT-Houston Rheumatology Division. 
Patients with SSc included 961 Caucasian, 178 African-American 
and 161 Hispanic subjects; normal local control totals were 539 
Caucasian, 263 African-American and 198 Hispanic subjects.
Only Hispanic patients with SSc and controls of Mexican or 
Central American ancestry were included.
HLA-DPB1 alleles were determined in 705 Caucasian patients 
with SSc and 287 Caucasian controls in the Scleroderma Registry. 
Only 82 African-American and Hispanic cases were studied for 
HLA-DPB1 alleles but were added to the Caucasian subjects 
for an overall comparison. All patients fulﬁ  lled the preliminary 
American College of Rheumatology criteria for the diagnosis 
of SSc34 or had three of the ﬁ  ve clinical features of the CREST 
syndrome (calcinosis, Raynaud’s phenomenon, esophageal dys-
function, sclerodactyly or telangiectasia). Patients having over-
lapping Sjögren’s syndrome, myositis or features of rheumatoid 
arthritis or systemic lupus were not excluded. Results of HLA 
allele frequencies in some of these patients have been reported 
previously23–25 30 and are included here. Because of the cross-
sectional nature of two of these three cohorts, reliable clinical 
information on speciﬁ  c organ involvement, such as pulmonary 
ﬁ  brosis, pulmonary hypertension or renal crisis, was not avail-
able to assess HLA associations. HLA registry controls were 
primarily spouse or friend controls, and GENISOS/Division 
controls were healthy medical centre personnel or blood bank 
donors from the local Houston area. All controls were screened 
for a history of any autoimmune diseases and excluded if posi-
tive. All study subjects provided written informed consent 
and the study was approved by the UTH Committee for the 
Protection of Human Subjects.
Autoantibody identiﬁ  cation
Antinuclear antibodies and ACA were determined in all patients 
with SSc by indirect immunoﬂ   uorescence on HEp-2 cells 
(Antibodies, Davis, California, USA). Immunodiffusion against 
calf thymus extract was used to determine the presence of ATA 
(Scl-70), anti-Ro/SS-A, anti-La/SS-B, anti-Smith (Sm) and anti-
RNP autoantibodies (Inova Diagnostics, San Diego, California, 
USA). ARA were determined using a commercially available 
enzyme-linked immunoassay (EIA) kit (MBL, Nagoya, Japan). 
AFA were determined only in those Division and GENISOS 
patients with SSc with a nucleolar antinuclear antibody pattern 
using immunoprecipitation.
HLA-class II genotyping
HLA-DQA1, -DQB1 and -DPB1 alleles were oligotyped and 
DRB1 alleles directly sequenced from extracted genomic DNA 
as previously described.
Statistical analyses
We used statistical analysis software SAS 9.1.3 and the SAS 
Genetic Package (SAS Institute, Cary, North Carolina, USA). χ2 
Tests or Fisher’s exact tests were used to compare HLA-class II 
allele frequencies between the normal control and SSc groups. 
Mantel–Haenszel tests were performed for the analysis of 
HLA-class II allelic frequencies to control for the confounding 
effects of ethnicity. In the online supplementary tables, we only 
reported the odds ratio (OR) and the corresponding 95% CI for 
p values <0.017, which accounts for the Bonferroni corrections 
by the number of comparisons for each HLA genotype (0.017 
= 0.05/3). LD coefﬁ  cients and the corresponding p values were 
computed to examine the allelic associations that occur between 
alleles at different loci using SAS Genetics software.
These χ2 data are presented in the supplementary tables. We 
then performed exact logistic regression for each of the HLA vari-
ants using dominant (D), additive (A) and recessive (R) model-
ling. To account for the multiple comparisons, we used a false 
discovery rate approach.35 We used an experimental threshold of 
α = 0.05 and accounted for 1000 potential multiple comparisons 
that we performed. Using these values for α and number of tests 
performed, a point signiﬁ  cance of 0.004 is considered statistically 
signiﬁ  cant. Nonetheless, p values of <0.05 also are selectively 
shown for alleles of interest and those which have been associ-
ated with SSc or its subgroups in other reports. Use of the 0.004 
as the threshold to declare signiﬁ  cance leads to a rough false 
discovery rate of 0.025. For LD analyses we used the procedure 
haplotype in the SAS Genetic Package. In addition, we examined 
frequencies of the presence of non-leucine residues at position 26 
in the DQ β chain based on our previous studies implicating this 
‘epitope’ (DQB1*26 epi) in susceptibility to the ACA in SSc.23 25
RESULTS
HLA-class II alleles in SSc
HLA-class II (DRB1, DQA1 and DQB1) genotyping was com-
pleted in 1300 SSc cases and 1000 normal controls and  HLA-DPB1 
in 705 white SSc cases and 287 white controls (tables 1–3 and 
supplementary tables 1 and 2).
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In African-Americans, the HLA-DRB1*0804/DQA1*0501/
DQB1*0301 haplotype was signiﬁ  cantly  increased,  while 
DRB1*1104 was not associated with SSc (table 2).
Signiﬁ  cant associations with SSc in Hispanic subjects were 
found for DRB1*1104 (OR = 4.99), DQA1*0501 (OR = 4.09) and 
DQB1*0301 (OR = 2.13), along with the DQB1*26 epi (OR = 1.81) 
(table 3). Again, DRB1*0701 and DQA1*0201 were decreased in 
frequency.
HLA-DQA1*0501 was signiﬁ   cantly more frequent in male 
(101/165 or 61%) than in female (583/1135 or 51%) patients 
with SSc (p = 0.02, OR = 1.49, 95% CI 1.06 to 2.12), thus con-
ﬁ  rming one earlier report.
HLA alleles in limited versus diffuse SSc
HLA associations with both limited and diffuse forms of SSc 
largely mirrored the ﬁ  ndings in the disease group as a whole, 
except in black patients with limited disease whose numbers 
were small (n = 54) (supplementary tables 3a and 4a by logistic 
regression and supplementary tables 3, 4 and 5 by χ2).
HLA allele frequencies in autoantibody subsets of SSc
Frequencies and ethnic differences in SSc autoantibodies are 
shown in online supplementary table 5. ACA were found to 
be associated with several class II haplotypes in white sub-
jects, including HLA-DRB1*0101, DQA1*0101 and DQB1*0501, 
DRB1*04, especially DRB1*0404, but weakly DRB1*0401 which 
carried DQB1*0301 alleles and weakly with DRB1*08 (*0801) and 
DQA1*0401 (table 4, supplementary table 6). The strongest asso-
ciated alleles were DRB1*0401 (OR = 8.98) in a recessive model, 
DRB1*0404 (OR = 4.18) in a dominant model, DQB1*0301 in a 
recessive model (OR = 3.41), DQB1*0501(dominant OR = 2.56) 
and the DQB1 26 epitope (OR = 2.93). No HLA-DPB1 alleles 
were associated with ACA.
No HLA alleles were associated with ACA in black subjects 
and only HLA-DRB1*0407 in Hispanic subjects.
ATA in white subjects were strongly associated with the HLA-
DRB1*1104, DQA1*0501, DQB1*0301 haplotype (OR = 6.93) 
and even more so with HLA-DPB1*1301 (OR = 14.02), both 
showing dominant models (table 5) (supplementary table 7).
The DRB1*1104 association also was present in the black sub-
jects and Hispanic subjects, as was the DQB1 26 epitope (table 
5, supplementary table 7). In addition, HLA-DRB1*08  alleles, 
DRB1*0804 in black subjects (OR = 3.42) and DRB1*0802 in 
Hispanic subjects (OR = 1.91) also were increased in these groups 
showing both additive and dominant effects. There appeared to 
be no negative or ‘protective’ effect from the DRB1*0701 haplo-
type. HLA-DPB1*1301 was highly signiﬁ  cantly associated with 
For all white patients with SSc versus ethnically matched 
controls, a strong association was found with HLA-DRB1*11, 
but speciﬁ  cally  with  DRB1*1104 and not with DRB1*1101, 
DQA1*0501 and DQB1*0301 also were signiﬁ  cantly increased. 
These three alleles constitute a haplotype with most DRB*11 
alleles including both DRB1*1101 and DRB1*1104.36 Given the 
highest odds ratio (OR = 2.48) being conferred by DRB1*1104 
rather than DQA1*0501 (OR = 2.29) or DQB1*0301 (OR = 1.50), 
the primary associated allele appeared likely to be DRB1*1104 in 
a dominant model. Also, the shared DQB1*26 epitope (absence 
of leucine in position 26) was increased (OR = 1.59). HLA-
DRB1*0404 also was signiﬁ  cantly increased (OR = 2.33); how-
ever, the strongest HLA-class II association with SSc was with 
HLA-DPB1*1301 (OR = 3.18). Testing for LD between HLA-
DPB1*1301 and DRB1*1104 showed an r2 value of 0.0001 and 
for DQB1*0301 0.009, thus demonstrating no signiﬁ  cant LD of 
this DR/DQ haplotype with DPB1*1301.
The HLA-DRB1*0701, DQA1*0201, DQB1*0202 haplo-
type was negatively associated with SSc in an additive model 
(HLA-DRB1*0701, DQA1*0201) and in dominant model (HLA- 
DQB1*0202) suggesting that it conferred a ‘protective’ effect 
(table 1). Similarly, the HLA-DRB1*1501, DQA1*0102, DQB1*0602 
haplotypes were signiﬁ  cantly decreased but in a recessive model.
Table 2  HLA-class II allelic frequencies signiﬁ  cantly associated with 
African-American patients with systemic sclerosis (SSc) compared with 
normal African-American controls using logistic regression
  SSc (%) Controls (%)
Model 
(D/R/A) p Value OR 95% CI
DRB1†
  *0804 10.2 3.6 D 0.0003 3.31 1.7 to 6.5
DQA1†
  *0501 34.2 24.1 A 0.003 3.55 1.6 to 8.1
1.63 1.1 to 2.5
DQB1†
 *0301 33.0 21.9 D <0.0001 2.44 1.6 to 3.7
†SSc cases (n = 178) versus normal controls (n = 263).
Table 3  HLA-class II allelic frequencies signiﬁ  cantly associated with 
Hispanic patients with systemic sclerosis (SSc) compared with normal 







(D/R/A) p Value OR 95% CI
DRB1†
  *1104 8.8 2.0 D 0.0003 4.99 2.0 to 12.4
  *0701 3.8 7.6 D 0.01 0.39 0.2 to 0.8
DQA1†
  *0501 29.9 21.7 R 0.002 4.09 1.6 to 10.4
  *0201 3.8 7.8 D 0.01 0.39 0.2 to 0.8
DQB1†
  *0301 24.2 14.9 D 0.003 2.13 1.3 to 3.5
 *DQB1 
26 epi
72.7 61.7 – 0.019 1.81 1.1 to 3.0
†SSc cases (n = 161) versus normal controls (n = 198).
Table 1  HLA-class II allelic frequencies signiﬁ  cantly associated with 
Caucasian patients with systemic sclerosis (SSc) compared with 







(D/R/A) p Value OR 95% CI
  *0404 4.3 1.9 D 0.003 2.33 1.3 to 4.1
  *0701 8.0 14.2 A <0.0001 0.39 0.1 to 1.1
0.43 0.3 to 0.6
  *11 13.5 8.2 D 0.0002 1.81 1.3 to 2.4
  *1104 7.1 3.0 D <0.0001 2.48 1.6 to 3.9
  *1501 11.0 14.3 R 0.0003 0.22 0.1 to 0.5
DQA1†
  *0102 18.1 21.3 R 0.0002 0.36 0.2 to 0.6
  *0201 7.6 14.4 A <0.0001 0.20 0.1 to 0.6
0.43 0.3 to 0.6
  *0501 31.6 24.0 A <0.0001 2.29 1.4 to 3.7
1.66 1.3 to 2.2
DQB1†
  *0202 5.4 10.3 D <0.0001 0.46 0.3 to 0.7
  *0301 23.0 16.8 D 0.002 1.50 1.2 to 1.9
  *0602 11.5 14.6 R 0.003 0.29 0.1 to 0.7
 *DQB1 
26 epi
64.4 53.8 – 0.0003 1.59 1.2 to 2.0
DPB1‡
 *1301 3.7 1.4 D 0.004 3.18 1.4 to 7.3
†SSc cases (n = 961) versus normal controls (n = 539); ‡SSc cases (n = 705) versus 
normal controls (n = 287) typed for HLA-DPB1.
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ATA when all ethnic groups were combined (p<0.0001, OR = 9.96) 
(supplementary table 7). Using logistic regression, there was 
no evidence of gene–gene interaction between DPB1*1301 and 
DRB1*1104 (p = 0.9863) or between DPB1*1301 and DQB1*0301 
(p = 0.9999) in the ATA positive group or in the total SSc group.
ARA were found to be most strongly associated in white 
subjects with HLA-DRB1*0404 (OR = 5.13) and DRB1*11 
alleles (OR = 1.55 for one copy, 6.78 for two copies), espe-
cially DRB1*1104 in additive and dominant models, respec-
tively (table 6) (supplementary table 8). In addition, a positive 
recessive effect was seen from DQB1*03 alleles (OR = 2.38), 
especially DQB1*0301 (OR = 1.50 for one copy, 3.77 for two 
copies). In black patients, the strongest associations were 
with DRB1*08 alleles (OR = 3.92), primarily DRB1*0804 (OR 
= 2.98), along with DQA1*0501 (OR = 3.10 for one copy, 6.03 
for two copies) in an additive model and DQB1*0301 (OR = 
3.60) showing a dominant effect. Among Hispanic subjects, 
DRB1*11, DQA1*0501 and the DQB1 26 epitope showed pos-
sible weak positive correlations, but the strongest association 
was with DQB1*0301 (OR = 4.07).
Other autoantibodies and HLA
The HLA-DRB1*1302, DQB1*0604 haplotype was most strongly 
associated with AFA in white subjects (p=0.0003, OR=6.87), 
along with the DQB1 26 epitope (p=0.0009, OR=1.60), while in 
black subjects DRB1*08 alleles (p=0.0003, OR=5.76), especially 
DQB1*0804 (p=0.002, OR=5.70), showed the strongest associa-
tions (supplementary tables 9 and 9a).
Anti-RNP, anti-Smith (Sm), anti-Ro/SSA and anti-La/SSB anti-
bodies showed no signiﬁ  cant HLA associations.
DISCUSSION
new to this study was the ﬁ   nding that the African HLA-
DRB1*0804 allele, along with DQA1*0501 and DQB1*0301, 
showed the most signiﬁ  cant associations in black subjects and 
recurred in those with diffuse disease, ATA, ARA and AFA.
Perhaps equally important was the susceptibility effect of other 
DQB1 alleles (besides *0301 and *0501) encoding polar amino 
acids at position 26 of the DQ β chain (DQB1*26 epi). Previously, 
we reported this shared epitope in the antigen binding cleft to be 
most important in the ACA autoimmune response25; however, 
this current larger study suggests that it occurs in the majority of 
patients with SSc regardless of ethnicity or autoantibody.
A second unreported and potentially ‘protective’ haplotype 
in white subjects, HLA-DRB1*1501, DQA1*0102, DQB1*0602, 
was signiﬁ  cantly decreased in a recessive model in Caucasian 
Table 4  HLA-class II allelic frequencies signiﬁ  cantly associated with 
anticentromere antibody positive Caucasian and Hispanic patients with 
systemic sclerosis (SSc) compared with ethnically matched normal 







(D/R/A) p Value OR 95% CI
Caucasian†
DRB1
  *01 21.0 12.5 D <0.0001 2.19 1.5 to 3.2
  *0101 16.6 8.2 D <0.0001 2.72 1.8 to 4.1
  *04 24.9 11.7 D 0.0004 1.90 1.3 to 2.7
  *0401 11.0 8.3 R 0.03 8.98 1.4 to 57.2
  *0404 5.5 1.9 D <0.0001 4.18 2.0 to 8.6
  *0701 2.9 14.2 A <0.0001 0.10 0.01 to 0.8
0.14 0.1 to 0.2
  *08 6.1 3.4 D 0.04 1.90 1.1 to 3.4
  *0801 4.8 2.0 D 0.03 3.17 1.5 to 6.6
  *11 11.9 8.2 D 0.02 1.67 1.1 to 2.6
 *1104 5.0 3.0 NS
  *1501 8.9 14.3 R 0.006 0.67 0.4 to 1.02
0.16 0.03 to 0.7
DQA1
  *0101 23.1 13.4 D <0.0001 2.57 1.8 to 3.7
  *0102 14.4 21.3 R 0.001 0.25 0.1 to 0.6
  *0201 3.0 14.4 A <0.0001 0.07 0.01 to 0.6
0.15 0.1 to 0.2
DQB1
  *0202 5.3 2.8 D <0.0001 0.14 0.07 to 0.3
  *0301 23.5 16.8 R 0.004 3.41 1.4 to 8.0
  *0302 14.6 9.4 D 0.007 2.04 1.2 to 3.4
  *0501 22.8 12.6 D <0.0001 2.56 2.0 to 3.7
 *DQB1  26 
epi
75.1 53.8 – <0.0001 2.93 2.0 to 4.2
DPB1
 *1301 1.5 1.4 NS
Hispanic‡
DRB1
 *0407 26.0 6.8 D 0.0009 5.07 2.0 to 12.9
†SSc cases (n = 281) versus normal controls (n = 539) in Caucasian subjects; ‡SSc 
cases (n = 25) versus normal controls (n = 198) in Hispanic subjects; NS=not 
signiﬁ  cant for any of the three models
Table 5  HLA-class II allelic frequencies signiﬁ  cantly associated with 
antitopoisomerase I antibody positive Caucasian, African-American 
and Hispanic patients with systemic sclerosis (SSc) compared with 







(D/R/A) p Value OR 95% CI
Caucasian†
  DRB1
   *0401 3.6 8.3 D 0.003 0.35 0.2  to  0.7
   *1101 6.2 3.8 D 0.03 2.13 1.1  to  4.1
   *1104 16.6 3.0 D <0.0001 6.93 3.9  to  12.2
  DQA1
   *0501 34.7 24.0 A <0.0001 2.01 0.9  to  4.7
2.80 1.8 to 4.2
  DQB1
   *0202 5.2 10.3 D 0.006 0.44 0.2  to  0.8
   *03 45.1 30.1 A 0.0004 3.30 1.8  to  6.2
1.76 1.1 to 2.7
   *0301 31.2 16.8 D <0.0001 3.20 2.1  to  4.8
   *DQB1 
26 epi
72.2 53.8 – <0.0001 2.47 1.6 to 3.8
  DPB1
   *1301 12.2 1.4 D <0.0001 14.02 6.5  to  30.3
African-American‡
  DRB1
   *08 12.5 5.5 D 0.04 2.64 1.1  to  6.1
   *0804 11.3 3.6 D 0.01 3.42 1.3  to  9.0
   *11 28.8 13.4 D 0.0005 3.55 1.8  to  7.2
   *1101 12.5 5.7 D 0.13 1.98 0.8  to  4.9
   *1104 8.8 1.9 D 0.007 4.66 1.6  to  13.4
  DQB1
   *0301 40.0 14.9 D 0.0002 3.90 1.9  to  8.1
   *DQB1 
26 epi
87.5 63.0 – 0.003 3.91 1.5 to 10.4
Hispanic§
  DRB1
   *08 23.6 9.9 D 0.08 2.00 0.9  to  4.4
   *0802 20.8 8.3 D 0.13 1.91 0.8  to  4.3
   *1104 22.2 2.0 D <0.0001 15.96 5.3  to  48.0
  DQA1
   *0401 26.4 9.1 D 0.008 3.05 1.4  to  6.7
   *0301 24.3 14.9 D 0.01 2.88 1.3  to  6.3
  DQB1
   *0402 25.7 8.1 D 0.003 3.46 1.6  to  7.7
   *DQB1 
26 epi
78.4 61.7 – 0.03 2.59 1.1 to 6.1
†SSc cases (n =154) versus normal controls (n = 539) in Caucasian subjects; ‡SSc 
cases (n = 40) versus normal controls (n = 263) in African-American subjects; §SSc 
cases (n = 37) versus normal controls (n = 198) in Hispanic subjects.
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subjects with SSc overall and in both limited and diffuse sub-
groups, as well as in those patients with ACA.
An HLA-DPB1 allele, DPB1*1301 in a dominant model, showed 
the highest odds ratios in SSc (OR = 3.18) and in both the limited 
(OR = 4.20) and diffuse (OR = 4.38) forms in Caucasian sub-
jects; however, these associations were completely explained 
by its strong correlation with ATA (OR = 14.02). Testing for 
LD of this DPB1 allele with the DRB1*1104 and DQB1*0301 
alleles showed that these were independently associated class 
II effects. Interestingly, the ATA response is strongly associated 
with pulmonary ﬁ  brosis in SSc and certain HLA-DP alleles have 
been clearly shown to promote susceptibility to occupationally 
acquired berylliosis, another ﬁ  brosing lung disease.40
Finally, ARA characteristically are markers of rapidly progres-
sive skin thickening and renal crises and this study is the ﬁ  rst 
to demonstrate that they occur in similar prevalences in each 
of these ethnic groups and are associated with certain class II 
MHC alleles.
In previous studies of HLA and ARA, there have been con-
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